Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl

References

• McCullough PA Bakris GL Owen WFJr Klassen PS Califf RM Slowing the progression of diabetic nephropathy and its cardiovascular consequences Am Heart J 2004 148 2 243 251 15308993
   PubMed Web of Science ®Google Scholar
• Ronco C McCullough PA Anker SD Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI) Contrib Nephrol 2010 165 54 67 20427956
   PubMed Web of Science ®Google Scholar
• McCullough PA Ahmad A Cardiorenal syndromes World J Cardiol 2011 3 1 1 9 21286212
   PubMedGoogle Scholar
• Agrawal V Kizilbash SH McCullough PA New therapeutic agents for diabetic kidney disease Therapy 2008 5 4 553 575
   Google Scholar
• McCullough PA Prevention of cardiorenal syndromes Contrib Nephrol 2010 165 101 111 20427960
   PubMed Web of Science ®Google Scholar
• Haraldsson B Jeansson M Glomerular filtration barrier Curr Opin Nephrol Hypertens 2009 18 4 331 335 19458528
   PubMed Web of Science ®Google Scholar
• Satchell SC Tooke JE What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008 51 5 714 725 18347777
   PubMed Web of Science ®Google Scholar
• Diez-Sampedro A Lenz O Fornoni A Podocytopathy in diabetes: a metabolic and endocrine disorder Am J Kidney Dis 2011 58 4 637 646 21719174
   PubMed Web of Science ®Google Scholar
• Jones DP Radical-free biology of oxidative stress Am J Physiol Cell Physiol 2008 295 4 C849 C868 18684987
   PubMed Web of Science ®Google Scholar
• Kang KW Lee SJ Kim SG Molecular mechanism of nrf2 activation by oxidative stress Antioxid Redox Signal 2005 7 11–12 1664 1673 16356128
   PubMed Web of Science ®Google Scholar
• Surh YJ Kundu JK Na HK Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals Planta Med 2008 74 13 1526 1539 18937164
   PubMed Web of Science ®Google Scholar
• Nguyen T Yang CS Pickett CB The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress Free Radic Biol Med 2004 37 4 433 441 15256215
   PubMed Web of Science ®Google Scholar
• Jaiswal AK Nrf2 signaling in coordinated activation of antioxidant gene expression Free Radic Biol Med 2004 36 10 1199 1207 15110384
   PubMed Web of Science ®Google Scholar
• Ungvari Z Bailey-Downs L Gautam T Adaptive induction of NF-E2-related factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia Am J Physiol Heart Circ Physiol 2011 300 4 H1133 H1140 21217061
   PubMed Web of Science ®Google Scholar
• Okouchi M Okayama N Alexander JS Aw TY NRF2-dependent glutamate-L-cysteine ligase catalytic subunit expression mediates insulin protection against hyperglycemia- induced brain endothelial cell apoptosis Curr Neurovasc Res 2006 3 4 249 261 17109620
   PubMed Web of Science ®Google Scholar
• Thomas MC Bardoxolone: augmenting the Yin in chronic kidney disease Diab Vasc Dis Res 2011 8 4 303 304 21933845
   PubMed Web of Science ®Google Scholar
• Agrawal A Chen B Liby KT Meyer C Bardoxolone methyl is renoprotective in a rat model of cisplatin induced acute kidney injury Proceedings of the 42nd Annual American Society of Nephrology Renal Week October 27–November 1, 2009 San Diego, CA Irving, TX Reata Pharmaceuticals
   Google Scholar
• Park HM Cho JM Lee HR Shim GS Kwak MK Renal protection by 3H-1,2-dithiole-3-thione against cisplatin through the Nrf2-antioxidant pathway Biochem Pharmacol 2008 76 5 597 607 18656455
   PubMed Web of Science ®Google Scholar
• Gupta A Khaira A Bardoxolone methyl: a targeted antioxidant Ren Fail 2011 33 10 1051 22013943
   PubMed Web of Science ®Google Scholar
• Ma R Bumeister R Stidham RD Bardoxolone methyl (BARD) inhibits inflammatory signaling in cultured mesangial cells Proceedings of the National Kidney Foundation Spring Clinical Meetings April 13–17, 2010 Lake Buena Vista, FL
   Google Scholar
• Hong DS Kurzrock R Supko JG Phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies European Organisation for Research and Treatment of Cancer, the National Cancer Institute, and the American Association for Cancer Research, the 2007 Symposium on Molecular Targets and Cancer Therapeutics (Abstract)
   Google Scholar
• Meyer C Bardoxolone, A Novel Oral Anti-Inflammatory Agent Shown to Improve Renal Function National Kidney Foundation Spring Clinical Meeting 2009 (Abstract)
   Google Scholar
• Pergola PE Krauth M Huff JW Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD Am J Nephrol 2011 33 5 469 476 21508635
   PubMed Web of Science ®Google Scholar
• Fu WJ Li BL Wang SB Changes of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltration Diabetes Res Clin Pract 2012 95 1 105 109 22015481
   PubMed Web of Science ®Google Scholar
• Schwartz S Denham D Hurwitz C Meyer C Pergola P Bardoxolone Methyl Improves Renal Function in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus American Society of Clinical Oncology 2008 (Abstract)
   Google Scholar
• Pergola PE Raskin P Toto RD Bardoxolone methyl and kidney function in CKD with type 2 diabetes N Engl J Med 2011 365 4 327 336 21699484
   PubMed Web of Science ®Google Scholar
• Fassett RG Venuthurupalli SK Gobe GC Coombes JS Cooper MA Hoy WE Biomarkers in chronic kidney disease: a review Kidney Int 2011 80 8 806 821 21697815
   PubMed Web of Science ®Google Scholar
• Zalesin KC Franklin BA Lillystone MA Differential loss of fat and lean mass in the morbidly obese after bariatric surgery Metab Syndr Relat Disord 2010 8 1 15 20 19929598
   PubMed Web of Science ®Google Scholar
• Kriz W LeHir M Pathways to nephron loss starting from glomerular diseases- insights from animal models Kidney Int 2005 67 2 404 419 15673288
   PubMed Web of Science ®Google Scholar
• Borkowski BJ Cheema Y Shahbaz AU Bhattacharya SK Weber KT Cation dyshomeostasis and cardiomyocyte necrosis: the Fleckenstein hypothesis revisited Eur Heart J 2011 32 15 1846 1853 21398641
   PubMed Web of Science ®Google Scholar
• Chakraborti S Chakraborti T Mandal M Mandal A Das S Ghosh S Protective role of magnesium in cardiovascular diseases: a review Mol Cell Biochem 2002 238 1–2 163 179 12349904
   PubMed Web of Science ®Google Scholar
• Asai T Nakatani T Tamada S Activation of transcription factors AP-1 and NF-kappaB in chronic cyclosporine A nephrotoxicity: role in beneficial effects of magnesium supplementation Transplantation 2003 75 7 1040 1044 12698095
   PubMed Web of Science ®Google Scholar
• Sakaguchi Y Shoji T Hayashi T Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease Diabetes Care 4 12 2012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Piantadosi CA Carraway MS Babiker A Suliman HB Heme oxygenase- 1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1 Circ Res 2008 103 11 1232 1240 18845810
   PubMed Web of Science ®Google Scholar
• Suliman HB Carraway MS Tatro LG Piantadosi CA A new activating role for CO in cardiac mitochondrial biogenesis J Cell Sci 2007 120 Pt 2 299 308 17179207
   PubMed Web of Science ®Google Scholar
• Blasi ER Heyen J Hemkens M McHarg A Ecelbarger CM Tiwari S Effects of Chronic PPAR-Agonist Treatment on Cardiac Structure and Function, Blood Pressure, and Kidney in Healthy Sprague-Dawley Rats PPAR Res 2009 2009 237865 19536351
   PubMed Web of Science ®Google Scholar
• Schrepper A Schwarzer M Schöpe M Amorim PA Doenst T Biphasic response of skeletal muscle mitochondria to chronic cardiac pressure overload – role of respiratory chain complex activity J Mol Cell Cardiol 2012 52 1 125 135 22100228
   PubMed Web of Science ®Google Scholar
• Schwartz S Denham D Hurwitz C Meyer C Pergola P Bardoxolone, a Novel Oral Anti-Inflammatory Agent Improves Glycemic Control in Type 2 Diabetics with Chronic Kidney Disease American Society of Clinical Oncology 2008 (Abstract)
   Google Scholar
• Pergola PE Schwartz S Denham D Bardoxolone Methyl Improves Renal Function with Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus World Congress of Nephrology 2009 (Abstract)
   Google Scholar
• Wigley WC Bumeister R Stidham RD Kambuj PA Laidlaw J Ferguson DA Bardoxolone Methyl (BARD) Activates Nrf2 and Inhibits NF-κB in Renal Cells American Society of Nephrology Renal Week 2009 (Abstract)
   Google Scholar
• Pergola PE Schwartz S Craig HA Meyer CJ Bardoxolone Methyl Improves Kidney Function in Patients with Type 2 Diabetes and Chronic Kidney Disease American society of Nephrology Renal Week 2009 (Abstract)
   Google Scholar
• Meyer CJ Ferguson DA Laidlaw J Bardoxolone Methyl Improves Markers of Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease American Society of Nephrology Renal Week 2009 (Abstract)
   Google Scholar
• Stidham RD Palaia T Bumeister R Ferguson DA Wigley CW Ragolia L Antioxidant Inflammation Modulators Increase Glucose Metabolism in Muscle Cells American Society of Nephrology Renal Week 2011 (Abstract)
   Google Scholar